Investigational drug · Phase 2
NNC0662-3168
Also called: Test product-A
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Overweight, Obesity, Type 2 Diabetes Mellitus.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "NNC0662-3168"
First trial start
2026
Nov 13, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NNC0662-3168", any sponsor or status.
Conditions studied
As listed on its trial records.
- Overweight
- Obesity
- Type 2 Diabetes Mellitus
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "NNC0662-3168" as an intervention, largest first.
- A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 DiabetesPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07940803 · 300 participants (planned) · Start Nov 13, 2026 · Primary completion Mar 25, 2028
Drug: NNC0662-3168 (Test product-A); Placebo matched to NNC0662-3168 (Test product-A) and 1 more · For: Overweight; Obesity; Type 2 Diabetes Mellitus
Sites: Tempe, Arizona; Lincoln, Nebraska
Newest research
PubMed records naming it or its code names, newest first.
- A Randomized, Double-Blind, Two-Treatment, Two-Period, Crossover Study Investigating the Systemic Bioavailability of a Novel Cocrystal Ubiquinol Formulation Compared with a Ubiquinone Formulation in Healthy Adults.
Mei X, Zhu B, Soni K, et al. · Clin Pharmacol Drug Dev 2026
- Palbociclib Capsule: A Bioequivalence Study in Healthy Subjects Under Fed Conditions to Compare Two Formulations.
Davanço MG, Vespasiano TP, Moisan J, et al. · Pharmaceutics 2026
- Evaluating the Effect of a Novel Digital Ostomy Device on Leakage Incidents, Quality of Life, Mental Well-Being, and Patient Self-Care: An Interventional, Multicentre Clinical Trial.
Brady RRW, Sheard D, Alty M, et al. · J Clin Med 2024
- Rationale for the topical use of a combination of diphenhydramine hydrochloride and lidocaine hydrochloride in the symptomatic treatment of histamine-dependent allergic and inflammatory skin reactions, accompanied by pruritus.
Doniec Z, Sielska M, Wróbel T, et al. · Postepy Dermatol Alergol 2024
- How reliable are test results from 17 laboratories on the basis of EN 1500 for a hand rub based on 80% (w/w)?
Suchomel M, Kampf G, Gebel J, et al. · J Hosp Infect 2024
- Effects of a combination of botanical actives on skin health and antioxidant status in post-menopausal women: A randomized, double-blind, placebo-controlled clinical trial.
Tumsutti P, Maiprasert M, Sugkraroek P, et al. · J Cosmet Dermatol 2022
Also in development for Overweight
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novo Nordisk.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.